Spire Healthcare Group (LON:SPI) Shares Down 17.8% After Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s stock price fell 17.8% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 184.60 ($2.39). 5,565,048 shares changed hands during trading, an increase of 727% from the average session volume of 672,747 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The firm has a market capitalization of £711.58 million, a PE ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 0.96. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The company has a 50-day moving average price of GBX 227.28 and a 200 day moving average price of GBX 229.74.

Spire Healthcare Group (LON:SPI) last posted its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. Analysts forecast that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.